全文获取类型
收费全文 | 466篇 |
免费 | 21篇 |
国内免费 | 2篇 |
专业分类
耳鼻咽喉 | 12篇 |
儿科学 | 17篇 |
妇产科学 | 5篇 |
基础医学 | 38篇 |
口腔科学 | 20篇 |
临床医学 | 28篇 |
内科学 | 108篇 |
皮肤病学 | 1篇 |
神经病学 | 21篇 |
特种医学 | 32篇 |
外科学 | 77篇 |
综合类 | 10篇 |
一般理论 | 2篇 |
预防医学 | 15篇 |
眼科学 | 47篇 |
药学 | 15篇 |
中国医学 | 2篇 |
肿瘤学 | 39篇 |
出版年
2023年 | 1篇 |
2022年 | 7篇 |
2021年 | 33篇 |
2020年 | 10篇 |
2019年 | 21篇 |
2018年 | 15篇 |
2017年 | 11篇 |
2016年 | 11篇 |
2015年 | 15篇 |
2014年 | 13篇 |
2013年 | 19篇 |
2012年 | 31篇 |
2011年 | 36篇 |
2010年 | 13篇 |
2009年 | 17篇 |
2008年 | 20篇 |
2007年 | 13篇 |
2006年 | 21篇 |
2005年 | 15篇 |
2004年 | 17篇 |
2003年 | 7篇 |
2002年 | 11篇 |
2001年 | 6篇 |
2000年 | 11篇 |
1999年 | 10篇 |
1998年 | 1篇 |
1997年 | 1篇 |
1994年 | 2篇 |
1993年 | 1篇 |
1992年 | 8篇 |
1991年 | 8篇 |
1990年 | 6篇 |
1989年 | 5篇 |
1988年 | 4篇 |
1987年 | 2篇 |
1986年 | 5篇 |
1985年 | 7篇 |
1982年 | 4篇 |
1981年 | 10篇 |
1980年 | 1篇 |
1979年 | 4篇 |
1978年 | 9篇 |
1977年 | 7篇 |
1976年 | 8篇 |
1975年 | 5篇 |
1974年 | 4篇 |
1972年 | 1篇 |
1969年 | 2篇 |
排序方式: 共有489条查询结果,搜索用时 15 毫秒
1.
2.
Vaida S. J.; Gaitini L. A.; Cook T. M.; Awan R.; Nolan J. P. 《British journal of anaesthesia》2004,92(6):905
EditorWe read with interest the case report by Awan andcolleagues,1 describing successful use of the ProSealTM laryngealmask airway (PLMA) after failed tracheal intubation in a parturientundergoing Caesarean section. After securing the airway withthe PLMA, the authors removed it and tried again to performtracheal intubation. We think that the PLMA can be left in placeand used as a definitive airway after failed intubation in Caesareansection. We report another case where the PLMA 相似文献
3.
Hashaam Akhtar Maham Afridi Samar Akhtar Hamaad Ahmad Sabahat Ali Sundas Khalid Sajid Mahmood Awan Shahzaib Jahangiri Yousef Saleh Khader 《JMIR Public Health and Surveillance》2021,7(5)
The COVID-19 outbreak started as pneumonia in December 2019 in Wuhan, China. The subsequent pandemic was declared as the sixth public health emergency of international concern on January 30, 2020, by the World Health Organization. Pakistan could be a potential hotspot for COVID-19 owing to its high population of 204.65 million and its struggling health care and economic systems. Pakistan was able to tackle the challenge with relatively mild repercussions. The present analysis has been conducted to highlight the situation of the disease in Pakistan in 2020 and the measures taken by various stakeholders coupled with support from the community to abate the risk of catastrophic spread of the virus. 相似文献
4.
A case of microscopic hemorrhage into the anterior chamber is described. Slit-lamp examination disclosed a steady fine stream of blood issuing from a tiny grayish bulblike microhemangioma at the pupillary border. Fluorescein biomicroscopy revealed several similar microhemangiomas on the borders of each pupil. It is presumed that minor ocular irritation, due either to poison ivy or to a menthol (0.70%) cream which the patient applied to her face, precipitated the microhyphema. 相似文献
5.
1 BACKGROUNDTheincidenceofCPis 0 .7per 1 0 0 0livebirths[1 ] .Becausecerebralpalsyinfluencesthewaychildrendevelop,itoftenresultsindevelop mentaldisability .Today ,more peoplehavecerebralpalsythananyotherdevelopmentaldis ability ,includingDownsyndrome,epilepsy ,andautism .Accordingtoasurveyconductedin1 986,2 .6%ofthepopulationofPakistaniaredisabled (includingbothphysicalandmentaldis abilities) .Childrenbetween 0~1 4 yearsinageconstitute 40 %ofthedisabled populationinPakistan .Routineme… 相似文献
6.
Zuhier A. Awan Shareefa A. AlGhamdi Nabil A. Alhakamy Solomon Z. Okbazghi Mohamed A. Alfaleh Shaimaa M. Badr-Eldin Hibah M. Aldawsari Mohammed A. S. Abourehab Hani Z. Asfour Shadi A. Zakai Mohammad W. Alrabia Aya A. Negm Mohamed A. El-Moselhy Sara S. Sharkawi Waleed Y. Rizg 《Drug delivery》2022,29(1):1536
Certain anticancer agents selectively target the nucleus of cancer cells. One such drug is 2-methoxyestradiol (2ME), which is used for treating lung cancer. To improve the therapeutic effectiveness of these agents, many new methods have been devised. 2ME was entrapped into the core of hydrophobic invasomes (INVA) covered with Phospholipon 90G and apamin (APA). The Box–Behnken statistical design was implemented to enhance the composition. Using Design-Expert software (Stat-Ease Inc., Minneapolis, MN), the INVA component quantities were optimized to obtain spherical particles with the smallest size, that is, a diameter of 167.8 nm. 2ME-INVA-APA significantly inhibited A549 cells and exhibited IC50 of 1.15 ± 0.04 µg/mL, which is lower than raw 2ME (IC50 5.6 ± 0.2 µg/mL). Post 2ME-INVA-APA administration, a significant rise in cell death and necrosis was seen among the A549 cells compared to those treated with plain formula or 2ME alone. This effect was indicated by increased Bax expression and reduced Bcl-2 expression, as well as mitochondrial membrane potential loss. Moreover, the cell cycle analysis showed that 2ME-INVA-APA arrests the G2-M phase of the A549 cells. Additionally, it was observed that the micellar formulation of the drug increased the cell count in pre-G1, thereby exhibiting phenomenal apoptotic potential. Furthermore, it up-regulates caspase-9 and p53 and downregulates TNF-α and NF-κβ. Collectively, these findings showed that our optimized 2ME-INVA-APA could easily seep through the cell membrane and induce apoptosis in relatively low doses. 相似文献
7.
Alrasadi K Awan Z Alwaili K Ruel I Hafiane A Krimbou L Genest J 《The American journal of cardiology》2008,102(10):1341-1347
To determine whether available lipid-modifying medication can increase high-density lipoprotein (HDL) cholesterol in well-defined genetic or familial HDL-deficiency states, we studied 19 men with HDL deficiency (HDL cholesterol <5th percentile for age and gender) 55 +/- 10 years of age. Concomitant risk factors included diabetes (n = 3) and hypertension (n = 7) and 8 patients had coronary artery disease. Molecular analysis revealed that 4 patients had a mutation in the ABCA1 gene. Patients were assigned to sequentially receive atorvastatin 20 mg/day, fenofibrate 200 mg/day, and extended-release niacin 2 g/day for 8 weeks, with a 4-week washout period between each treatment. Patients in whom a statin was required, according to current treatment guidelines, were kept on atorvastatin throughout the study. Baseline HDL cholesterol level was 0.63 +/- 0.12 mmol/L (24 +/- 5 mg/dl), triglycerides 2.01 +/- 0.98 mmol/L (180 +/- 86 mg/dl), and low-density lipoprotein (LDL) cholesterol 2.29 +/- 0.95 mmol/L (94 +/- 39 mg/dl). Mean percent changes in HDL cholesterol on atorvastatin, fenofibrate, and niacin were -6% (p = NS), +6% (p = NS), and +22% (p <0.05), respectively. Furthermore, niacin significantly increased the large alpha-1 apolipoprotein A-I-containing HDL subspecies (12 to 17 nm). In conclusion, niacin was the only effective drug to increase HDL cholesterol. The absolute increase in HDL cholesterol, approximately 0.10 mmol/L (3.9 mg/dl), is of uncertain clinical significance. Biomarkers of HDL-mediated cellular cholesterol efflux were not changed by niacin therapy. Atorvastatin or fenofibrate had little effect on HDL cholesterol; atorvastatin decreased the total cholesterol/HDL cholesterol ratio by 26%. Fenofibrate did not change HDL cholesterol levels and caused an increase in LDL cholesterol. Aggressive LDL cholesterol lowering may be the strategy of choice in such patients. 相似文献
8.
Melissa Wasserstein Laila Arash-Kaps Antonio Barbato Renata Gallagher Roberto Giugliani Norberto Guelbert Carla Hollak Takayuki Ikezoe Robin Lachmann Olivier Lidove Paulina Mabe Eugen Mengel Maurizio Scarpa Ebubekir Senates Michel Tchan Jesus Villarrubia Yixin Chen Maria Iram Awan Monica Kumar 《Molecular genetics and metabolism》2021
9.
10.